Table 1 Patient characteristics and... | American Society of Hematology

Table 1

Patient characteristics and MAGE-specific CD8⁺ T-cell response before and during treatment with azacitidine/VPA: summary of results from immune monitoring

Patient number	Age, y/sex	Diagnosis	Date of diagnosis	Previous treatment	Disease status pretreatment	Karyotype		CTA-specific CD8⁺ T-cell response (% lymphocytes)								Response to treatment
Patient number	Age, y/sex	Diagnosis	Date of diagnosis	Previous treatment	Disease status pretreatment	Karyotype	Pretreatment	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Antigen	Response to treatment
UPIN01	71/M	MDS-RAEB	Oct 2005	None	MDS RAEB II	Standard risk	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		PR 190
UPIN02	68/F	Secondary AML	June 2008	DA, FLAG	Refractory AML	Standard risk	Negative	Negative	Negative	Negative	Negative					PR 53
UPIN03	70/M	Secondary AML	June 2007	DA ×2	Relapsed AML	Standard risk	Negative	Negative	Negative	Negative	Negative	0.49	0.05	1.1*	MAGE A2_212-220	PR 354§
UNPIN04	76/M	Secondary AML	Oct 2008	DClo	Refractory AML	Standard risk	Negative	0.05	0.1	0.2					MAGE A2_157-166	SD
UPIN05	82/F	MDS –RAEB	Jan 2009	None	MDS –RAEB	Standard risk	Negative									NE
UPIN06	54/F	Secondary AML	Jan 2008	DA, MidAC, RIC allotransplant	Relapsed AML	Standard risk	Negative									NE
UPIN07	61/M	Primary AML	April 2008	High-dose cytarabine ×3	Relapsed AML	Poor risk	Negative									NE
UPIN08	72/M	Secondary AML	Jan 2009	None	Secondary AML	Poor risk	Negative									NE
UPIN09	74/M	Secondary AML	Jan 2009	DA, high-dose cytarabine; high-dose cytarabine (×2) on relapse	Relapsed AML	Standard risk	Negative	0.01	0.02	0.004	0.1				MAGE C2_336-344/RAGE 1_32-40	CR 267§
UPIN10	67/F	Primary AML	Nov 2003	DA×2, MACE, MidAC, high-dose cytarabine; high-dose cytarabine (×2)	Relapsed AML	Standard risk	0.042	0.085	0.014	0.1					MAGE A2_157-166	CR 56
UPIN11	51/M	Secondary AML	Feb 2009	DA	Refractory AML	Standard risk	Negative	Negative	Negative	0.05					MAGE A2_212-220	PR 140
UPIN12	55/M	Primary AML	May 2009	None	De novo AML	Standard risk	Negative	Negative	Negative	Negative						CR 79
UPIN13	70/M	Primary AML	Nov 2008	DA	Relapsed AML	Poor risk	Negative	Negative	Negative							CR 148
UPIN14	70/M	MDS-RAEB	Sep 2007	None	MDS-RAEB	Standard risk	Negative	Not performed	Not performed	Not performed	Not performed	0.01 (cycle 16)	0.95 (cycle 18)*		MAGE-A3_167-176	CR 799§
UPIN15	68/M	Secondary AML	June 2009	MidAC	Refractory AML	Standard risk	Negative	Negative	Negative	0.07	0.1	0.01†			RAGE-1_352-360	SD
UPIN16	71/F	Secondary AML	March 2008	None	De novo AML	Standard risk	Negative									NE
UPIN17	80/M	MDS-RAEB	May 2007	MidAC	Relapsed AML	Standard risk	Negative	Negative	0.47‡						RAGE-A1_11-20	CR 29
UPIN18	63/M	Primary AML	Dec 2008	DA, FLAG, RIC, allogeneic transplant	Relapsed AML	Poor risk	Negative	Negative	0.02	0.004	0.02†				MAGE-A2_212-220	PR 63
UPIN19	71/F	Primary AML	Oct 2009	Cytosine	Refractory AML	Standard risk	Negative									NE
UPIN20	67/F	MDS-RAEB	Aug 2007	Azacitidine, RIC, allograft	Relapsed MDS	Standard risk	Negative	0.02	0.10						MAGE-A1_96-104	SD
UPIN 21	46/F	Primary AML	Jan 2009	MidAC, RIC, allograft	Relapsed AML	Standard risk	Negative	0.18	0.2						Peptide pool A	PR

Patient number	Age, y/sex	Diagnosis	Date of diagnosis	Previous treatment	Disease status pretreatment	Karyotype		CTA-specific CD8⁺ T-cell response (% lymphocytes)								Response to treatment
Patient number	Age, y/sex	Diagnosis	Date of diagnosis	Previous treatment	Disease status pretreatment	Karyotype	Pretreatment	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Antigen	Response to treatment
UPIN01	71/M	MDS-RAEB	Oct 2005	None	MDS RAEB II	Standard risk	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		PR 190
UPIN02	68/F	Secondary AML	June 2008	DA, FLAG	Refractory AML	Standard risk	Negative	Negative	Negative	Negative	Negative					PR 53
UPIN03	70/M	Secondary AML	June 2007	DA ×2	Relapsed AML	Standard risk	Negative	Negative	Negative	Negative	Negative	0.49	0.05	1.1*	MAGE A2_212-220	PR 354§
UNPIN04	76/M	Secondary AML	Oct 2008	DClo	Refractory AML	Standard risk	Negative	0.05	0.1	0.2					MAGE A2_157-166	SD
UPIN05	82/F	MDS –RAEB	Jan 2009	None	MDS –RAEB	Standard risk	Negative									NE
UPIN06	54/F	Secondary AML	Jan 2008	DA, MidAC, RIC allotransplant	Relapsed AML	Standard risk	Negative									NE
UPIN07	61/M	Primary AML	April 2008	High-dose cytarabine ×3	Relapsed AML	Poor risk	Negative									NE
UPIN08	72/M	Secondary AML	Jan 2009	None	Secondary AML	Poor risk	Negative									NE
UPIN09	74/M	Secondary AML	Jan 2009	DA, high-dose cytarabine; high-dose cytarabine (×2) on relapse	Relapsed AML	Standard risk	Negative	0.01	0.02	0.004	0.1				MAGE C2_336-344/RAGE 1_32-40	CR 267§
UPIN10	67/F	Primary AML	Nov 2003	DA×2, MACE, MidAC, high-dose cytarabine; high-dose cytarabine (×2)	Relapsed AML	Standard risk	0.042	0.085	0.014	0.1					MAGE A2_157-166	CR 56
UPIN11	51/M	Secondary AML	Feb 2009	DA	Refractory AML	Standard risk	Negative	Negative	Negative	0.05					MAGE A2_212-220	PR 140
UPIN12	55/M	Primary AML	May 2009	None	De novo AML	Standard risk	Negative	Negative	Negative	Negative						CR 79
UPIN13	70/M	Primary AML	Nov 2008	DA	Relapsed AML	Poor risk	Negative	Negative	Negative							CR 148
UPIN14	70/M	MDS-RAEB	Sep 2007	None	MDS-RAEB	Standard risk	Negative	Not performed	Not performed	Not performed	Not performed	0.01 (cycle 16)	0.95 (cycle 18)*		MAGE-A3_167-176	CR 799§
UPIN15	68/M	Secondary AML	June 2009	MidAC	Refractory AML	Standard risk	Negative	Negative	Negative	0.07	0.1	0.01†			RAGE-1_352-360	SD
UPIN16	71/F	Secondary AML	March 2008	None	De novo AML	Standard risk	Negative									NE
UPIN17	80/M	MDS-RAEB	May 2007	MidAC	Relapsed AML	Standard risk	Negative	Negative	0.47‡						RAGE-A1_11-20	CR 29
UPIN18	63/M	Primary AML	Dec 2008	DA, FLAG, RIC, allogeneic transplant	Relapsed AML	Poor risk	Negative	Negative	0.02	0.004	0.02†				MAGE-A2_212-220	PR 63
UPIN19	71/F	Primary AML	Oct 2009	Cytosine	Refractory AML	Standard risk	Negative									NE
UPIN20	67/F	MDS-RAEB	Aug 2007	Azacitidine, RIC, allograft	Relapsed MDS	Standard risk	Negative	0.02	0.10						MAGE-A1_96-104	SD
UPIN 21	46/F	Primary AML	Jan 2009	MidAC, RIC, allograft	Relapsed AML	Standard risk	Negative	0.18	0.2						Peptide pool A	PR

M indicates male; MDS, myelodysplasia; RAEB, refractory anemia with excess blasts; Oct, October; F, female; DA, daunorubicin/cytarabine; FLAG, fludarabine/cytarabine/GCSF; DClo, daunorubicin/clofarabine; SD, stable disease; Jan, January; NE, not evaluable; MidAC, mitoxantrone/cytarabine; RIC, reduced-intensity conditioning; Nov, November; MACE, amsacrine/cytarabine/etoposide; Feb, February; Sep, September; Dec, December; and Aug, August. Peptide pool A comprised MAGE-A2_157-166; MAGE A2_212-220 MAGE-C2_336-344; RAGE-1_11-20; RAGE 1_32-40; CR, clinical response; and PR, partial response.

Indicates patient with notable increase in absolute lymphocyte count (from 2.1 at cycle 6 to > 6.6 at cycle 8), as well as increase in tumor blasts in the blood.

†

Indicates T-cell response additionally quantified by IFN-γ capture assay.

‡

Indicates patient in whom responses were found to all 5 peptides in peptide pool A, with RAGE-A1_11-20 being dominant.

Indicates patients still responding to treatment.

View Large

This Feature Is Available To Subscribers Only